Abivax, Celyad, Circassia and Genticel – these are all European Biotechs that took a hit after failing key clinical trials in June. How are they doing now?
Four different public Biotechs suffered setbacks in some of their advanced clinical trials. And, as always, the words ‘failed to meet primary endpoint‘ weren’t very popular with investors…
One of them was Toulouse-based Genticel. This Biotech had already suffered a major drop back in January, when their Phase II results for HPV infection failed to meet the primary endpoint in the middle of the trial.
Abivax is another French antiviral Biotech that didn’t have it easy. Its frontrunner candidate for Hepatitis B (which was 2 years ahead of competition) has received a tough sentence –